Myriad Current Deferred Revenue from 2010 to 2024
| MYGN Stock | USD 15.49 0.37 2.45% |
Current Deferred Revenue | First Reported 2001-03-31 | Previous Quarter 600 K | Current Value -17.8 M | Quarterly Volatility 8 M |
Check Myriad Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Myriad Genetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 M, Total Revenue of 414.1 M or Gross Profit of 327.5 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.22 or PTB Ratio of 1.44. Myriad financial statements analysis is a perfect complement when working with Myriad Genetics Valuation or Volatility modules.
Myriad | Current Deferred Revenue |
Latest Myriad Genetics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Myriad Genetics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Myriad Genetics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Myriad Genetics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Myriad Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 3,068,692 | |
| Geometric Mean | 1,832,392 | |
| Coefficient Of Variation | 155.84 | |
| Mean Deviation | 2,520,799 | |
| Median | 2,043,000 | |
| Standard Deviation | 4,782,382 | |
| Sample Variance | 22.9T | |
| Range | 19.3M | |
| R-Value | (0.43) | |
| Mean Square Error | 20T | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | (461,309) | |
| Total Sum of Squares | 320.2T |
Myriad Current Deferred Revenue History
About Myriad Genetics Financial Statements
Myriad Genetics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Myriad Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 540 K | 513 K |
Pair Trading with Myriad Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.Moving together with Myriad Stock
| 0.65 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.9 | ME | 23Andme Holding | PairCorr |
| 0.76 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Myriad Stock
| 0.72 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.47 | KZR | Kezar Life Sciences | PairCorr |
| 0.42 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.39 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Myriad Genetics Correlation against competitors. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.